Modified natural killer cells and natural killer cell lines having increased cytotoxicity
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
NK cells and NK cell lines are modified to increase cytotoxicity, wherein the cells and compositions thereof have a use in the treatment of cancer. Production of modified NK cells and NK cell lines is via genetic modification to add mutant (variant) TRAIL ligand expression.
Core Innovation
The invention relates to modified natural killer (NK) cells and NK cell lines engineered for cancer therapy by expressing a TRAIL mutant. The TRAIL mutant has an increased affinity for a TRAIL receptor and/or a decreased affinity for a decoy TRAIL receptor relative to wildtype TRAIL. The approach is described in the context of treating a TRAIL-expressing blood cancer and administering the modified NK cell or NK cell line to an individual in need thereof.
A further aspect targets DR4-expressing blood cancers by administering an NK cell or NK cell line modified to express a TRAIL mutant with increased affinity for a DR4 TRAIL receptor relative to wildtype TRAIL. In this embodiment, the TRAIL mutant comprises mutations G131R, R149I, S159R and S215D. The claimed blood cancer limitation is explicitly tied to DR4 expression.
The disclosed engineering framework further includes optional modification steps directed at reducing or abolishing expression of checkpoint inhibitory receptors to increase cytotoxicity. The checkpoint inhibitory receptors enumerated include CD96 (TACTILE), CD152 (CTLA4), CD223 (LAG-3), CD279 (PD-1), CD328 (SIGLEC7), SIGLEC9, TIGIT, and TIM-3. The overall system can include combinations with agents that upregulate DR5 and/or DR4 expression and, as described in the provided summary, may be combined with other receptor-based modifications.
Claims Coverage
The independent claims are directed to two methods of treating blood cancer using NK cells or NK cell lines modified to express a TRAIL mutant. The inventive features focus on altered receptor and decoy receptor affinities, a DR4-specific mutant with defined substitutions, and the linkage of treatment to TRAIL receptor or DR4 expression.
Administering NK cells expressing affinity-altered TRAIL mutant for TRAIL-expressing blood cancer
Administer to an individual a natural killer (NK) cell or NK cell line modified to express a TRAIL mutant, where the TRAIL mutant has an increased affinity for a TRAIL receptor and/or a decreased affinity for a decoy TRAIL receptor, relative to wildtype TRAIL, for treating a TRAIL-expressing blood cancer.
Administering NK cells expressing DR4-affinity TRAIL mutant with specified substitutions for DR4-expressing blood cancer
Administer to an individual a natural killer (NK) cell or NK cell line modified to express a TRAIL mutant, where the TRAIL mutant has an increased affinity for a DR4 TRAIL receptor, relative to wildtype TRAIL, and where the TRAIL mutant comprises mutations G131R, R149I, S159R and S215D, to treat a DR4-expressing blood cancer.
Claim coverage centers on administering modified NK cells or NK cell lines that express TRAIL mutants with increased affinity for TRAIL receptors, including DR4-specific increased affinity, and in one claim decreased affinity for decoy TRAIL receptors, with one independent claim specifying a DR4-affinity TRAIL mutant defined by mutations G131R, R149I, S159R and S215D.
Stated Advantages
Increased cytotoxicity for cancer therapy.
Documented Applications
Treating a TRAIL-expressing blood cancer by administering a modified natural killer (NK) cell or NK cell line expressing a TRAIL mutant.
Treating a DR4-expressing blood cancer by administering a modified NK cell or NK cell line expressing a DR4-affinity TRAIL mutant comprising mutations G131R, R149I, S159R and S215D.
Interested in licensing this patent?